NCT07479667

An Antibody-armored Dendritic Cell in Patients With Solid Tumors

An Exploratory, Single-arm, Open-label Study to Evaluate the Safety and Tolerability of Antibody-armored Dendritic Cell Injection Following a Single Administration in Patients With Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (estimated)
• Sponsor: Shanghai Cell Therapy Group Co.,Ltd · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study is a single-arm, open-label, single-administration dose-escalation study.

Conditions

• Solid Cancers
• Adjuvant Therapy

Interventions

Type	Name	Description
BIOLOGICAL	Armored Dendritic Cell Injection	Armored dendritic cells are administered via multiple subcutaneous injections.

Timeline

• Start date: 2026-02-05
• Primary completion: 2028-12-31
• Completion: 2029-06-30
• First posted: 2026-03-18
• Last updated: 2026-03-18

Locations

1 site across 1 country: China